Saved local watchlist · Deprioritization mentions · sorted by registry update date
Candidate queue
877 active trial–asset records · showing latest 25 · no composite ranking
An ingestion window is pending. Refresh resumes the next page.
| Asset / trial | Sponsor / phase | Status / stopping reason | Independent scores | Source |
|---|---|---|---|---|
| Sodium ValproateNCT00221637 | University Hospital, BordeauxPHASE2, PHASE3 | TERMINATED slow recruitment and treatments beyond expiry date | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-06-13 |
| baclofen (drug)NCT00221689 | University Hospital, BordeauxPHASE2 | TERMINATED very slow recruitment and treatments beyond expiry date | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-06-13 |
| gemcitabineNCT00116389 | Point TherapeuticsPHASE2 | TERMINATED FDA Hold May 2007 | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-06-08 |
| talabostat mesylate tabletsNCT00116389 | Point TherapeuticsPHASE2 | TERMINATED FDA Hold May 2007 | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-06-08 |
| docetaxelNCT00243204 | Point TherapeuticsPHASE3 | TERMINATED FDA Hold May 2007 | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-06-08 |
| talabostat mesylateNCT00243204 | Point TherapeuticsPHASE3 | TERMINATED FDA Hold May 2007 | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-06-08 |
| pemetrexedNCT00290017 | Point TherapeuticsPHASE3 | TERMINATED FDA Hold May 2007 | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-06-08 |
| talabostatNCT00290017 | Point TherapeuticsPHASE3 | TERMINATED FDA Hold May 2007 | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-06-08 |
| controlled-release levodopa / carbidopaNCT00174239 | PfizerPHASE4 | TERMINATED See Detailed Description for termination reason. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-05-25 |
| cabergolineNCT00174239 | PfizerPHASE4 | TERMINATED See Detailed Description for termination reason. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-05-25 |
| NitroprussideNCT00128791 | Soroka University Medical CenterPHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-05-25 |
| CC-401NCT00126893 | Celgene CorporationPHASE1 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-05-15 |
| INNO-105NCT00255333 | Innovive PharmaceuticalsPHASE1 | TERMINATED Development of this compound was discontinued. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-05-14 |
| Motexafin Gadolinium InjectionNCT00080028 | Pharmacyclics LLC.PHASE1 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-05-08 |
| Anecortave Acetate Sterile Suspension (15 mg)NCT00211406 | Manhattan Eye, Ear & Throat HospitalPHASE1 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2007-05-08 |
| Pro-Pe adhesive tabletNCT00281723 | Hadassah Medical OrganizationPHASE2 | SUSPENDED The company which holds the patent was not interested. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-05-08 |
| anecortave acetateNCT00211471 | Manhattan Eye, Ear & Throat HospitalPHASE2 | TERMINATED poor enrollment | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2007-05-07 |
| pegvisomant/placebo loading dose 80mg sc, thereafter 20mg daily for 2 weeksNCT00468624 | The Christie NHS Foundation TrustNA | TERMINATED recruitment completed | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2007-05-03 |
| AbciximabNCT00167765 | University of ZurichPHASE3 | TERMINATED Higher hemorrhage rates of Abciximab in ABESST II trial | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-05-03 |
| AbciximabNCT00126139 | University of ZurichPHASE3 | TERMINATED Higher hemorrhage rates of Abciximab in ABESST II trial | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-05-03 |
| HEMOBAG AssessmentNCT00176657 | University of Medicine and Dentistry of New JerseyPHASE2 | TERMINATED Inability to attain sufficient numbers of subjects | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-05-01 |
| DetemirNCT00135070 | The Royal Bournemouth HospitalPHASE4 | TERMINATED No documentation with MHRA to support clinical trial of a medicinal product. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-05-01 |
| LevemirNCT00467246 | The Royal Bournemouth HospitalNA | WITHDRAWN Ethics approval denied | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2007-04-30 |
| Influenza vaccineNCT00466037 | Tel-Aviv Sourasky Medical CenterNA | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-04-27 |
| methotrexateNCT00233558 | AbbottPHASE4 | TERMINATED Study terminated due to low subject enrollment. Safety results consistent with product label. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-04-24 |
Recent ingestion runs
| Source | Studies seen | Candidate writes | Status / finished |
|---|---|---|---|
| pubmed | 240 | 100 | finished2026-09-21T03:58:28.397783+00:00 |
| pubmed | 0 | 0 | failed2026-09-21T03:48:59.232056+00:00 |
| sec | 0 | 0 | finished2026-09-21T03:48:59.212906+00:00 |
| ClinicalTrials.gov | 300 | 258 | partial2026-09-21T03:48:59.189357+00:00 |
| ClinicalTrials.gov | 300 | 305 | Legacy run2026-09-21T03:45:47.341408+00:00 |
| ClinicalTrials.gov | 300 | 348 | Legacy run2026-09-21T03:38:48.082427+00:00 |